GSF: Virology & Infectious Diseases RFP - HBV: B-PRO Grant

GSF: Virology & Infectious Diseases RFP - HBV: B-PRO Grant

Status: ACTIVE
Funder: Gilead Sciences, Inc.
Last Updated: May 09, 2025

Summary

The GSF: Virology & Infectious Diseases RFP - HBV: B-PRO aims to address chronic hepatitis B (CHB), a significant public health concern despite available vaccines and antiviral therapies. This initiative emphasizes the importance of understanding patient-reported outcomes (PROs) alongside clinical data, enhancing patient care and health outcomes. Evaluating the impact of HBV treatments on patients' quality of life and daily experiences is crucial for shaping therapeutic strategies and improving healthcare policies for HBV patients.

Overview

NOTE: Please apply by 23:59 PM (in your time zone) before the submission window closes. Virology & Infectious Diseases RFP - HBV: B-PRO Chronic hepatitis B (CHB) can be a life-threatening liver infection caused by the hepatitis B virus (HBV). CHB continues to be a major public health issue despite the availability of an effective vaccine and antiviral therapies. Untreated individuals with CHB have an estimated 30%-40% lifetime risk of cirrhosis or hepatocellular carcinoma (HCC). Therapy for HBV has greatly improved, with the availability of effective and safe oral antivirals with high barriers to resistance. Additionally, treatment has been shown to decrease the occurrence of complications such as liver decompensation and hepatocellular carcinoma. Understanding the patient experience, beyond clinical endpoints, is critical for optimizing patient care and improving overall health outcomes. Utilizing patient-reported outcomes (PROs) in addition to clinical data as a tool to provide insight into patients’ perspectives on treatment experience, quality of life, and overall well-being can shed light on how HBV treatment affects individuals’ daily lives and influence perspectives on their healthcare and well-being. Evaluating the impact of HBV treatment on patient-reported outcomes is a gap that can complement clinical data to shape therapeutic strategies, clinical decision making, educational initiatives and policy decisions to enhance the outcomes for HBV patients. Funding Any proposal greater than $200,000 should be discussed with your Gilead Medical Science Liaison prior to submission. The proposed budget should include overhead costs and applicable taxes. Proposed overhead costs cannot exceed 30% of the total budget.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.